Prescription drug · ANDA
Pemetrexed (pemetrexed disodium) NDC 25021-260
Pemetrexed disodium hemipentahydrate 100 mg/4.2mL · Injection, Powder, Lyophilized, For solution · Intravenous · Sagent Pharmaceuticals
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 25021-260-10 | 25021026010 | 1 VIAL in 1 CARTON (25021-260-10) / 4.2 mL in 1 VIALMarketed from Dec 15, 2024 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Pemetrexed
- Generic name (nonproprietary)
- pemetrexed disodium
- Active ingredients
- Pemetrexed disodium hemipentahydrate — 100 mg/4.2mL
- Dosage form
- Injection, Powder, Lyophilized, For solution
- Route
- Intravenous
- Labeler
- Sagent Pharmaceuticals
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 204890
- Marketing start
- Listing expires
- Other FDA classes
- Folic Acid Metabolism Inhibitors (Mechanism)
- Identifiers
- Product ID 25021-260_54581a8b-ea74-4481-9b05-a802a13dcd15SPL ID 54581a8b-ea74-4481-9b05-a802a13dcd15
- Pharmacologic class
- Folate Analog Metabolic Inhibitor
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
- NDC on a medical claim
N425021026010followed by a unit qualifier and the quantityPackage 25021-0260-10. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
The FDA listing for this product does not reference a label (SPL) set.
Other NDCs under ANDA 204890
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Pemetrexedpemetrexed disodium | Pemetrexed disodium hemipentahydrate 500 mg/20mL | Injection, Powder, Lyophilized, For solutionIntravenous | Sagent Pharmaceuticals | 25021-261 |
| Pemetrexedpemetrexed disodium | Pemetrexed disodium hemipentahydrate 500 mg/20mL | Injection, Powder, Lyophilized, For solutionIntravenous | BluePoint Laboratories | 68001-539 |
| Pemetrexedpemetrexed disodium | Pemetrexed disodium hemipentahydrate 100 mg/4mL | Injection, Powder, Lyophilized, For solutionIntravenous | BluePoint Laboratories | 68001-538 |
| Pemetrexedpemetrexed disodium | Pemetrexed disodium hemipentahydrate 100 mg/4mL | Injection, Powder, Lyophilized, For solutionIntravenous | Qilu Pharmaceutical Co., Ltd. | 67184-0503 |
| Pemetrexedpemetrexed disodium | Pemetrexed disodium hemipentahydrate 500 mg/20mL | Injection, Powder, Lyophilized, For solutionIntravenous | Qilu Pharmaceutical Co., Ltd. | 67184-0504 |